×
BeiGene Cash on Hand 2014-2024 | ONC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BeiGene cash on hand for the quarter ending December 31, 2024 was
$2.627B
, a
17.16% decline
year-over-year.
BeiGene cash on hand for 2024 was
$2.627B
, a
17.16% decline
from 2023.
BeiGene cash on hand for 2023 was
$3.172B
, a
30.06% decline
from 2022.
BeiGene cash on hand for 2022 was
$4.535B
, a
31.47% decline
from 2021.
View More
BeiGene Cash on Hand 2014-2024 | ONC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BeiGene cash on hand for 2024 was
$2.627B
, a
17.16% decline
from 2023.
BeiGene cash on hand for 2023 was
$3.172B
, a
30.06% decline
from 2022.
BeiGene cash on hand for 2022 was
$4.535B
, a
31.47% decline
from 2021.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.9B
Amgen (AMGN)
$158.1B
Gilead Sciences (GILD)
$134.2B
Vertex Pharmaceuticals (VRTX)
$121.1B
Bristol Myers Squibb (BMY)
$111.6B
CSL (CSLLY)
$80.7B
GSK (GSK)
$75.7B
Regeneron Pharmaceuticals (REGN)
$75B
Argenex SE (ARGX)
$38.9B
Alnylam Pharmaceuticals (ALNY)
$32.4B
BioNTech SE (BNTX)
$28.7B
Biogen (BIIB)
$20B
Illumina (ILMN)
$16.3B
Insmed (INSM)
$15B
Genmab (GMAB)
$14.5B
Genmab (GNMSF)
$14.4B
Moderna (MRNA)
$13.8B
Intra-Cellular Therapies (ITCI)
$13.7B
Incyte (INCY)
$13.6B
BioMarin Pharmaceutical (BMRN)
$12.5B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Bio-Techne Corp (TECH)
$10.4B
Vaxcyte (PCVX)
$10.4B
Sarepta Therapeutics (SRPT)
$10.2B
Exelixis (EXEL)
$9.8B
Ascendis Pharma (ASND)
$9.4B
Exact Sciences (EXAS)
$9.3B
Bio-Rad Laboratories (BIO.B)
$8.7B
QIAGEN (QGEN)
$8.7B
Repligen (RGEN)
$8.4B